Chemicals

Mazdutide IBI362 China Suppliers High Purity Peptide Factory

Premium Mazdutide 10MG and 20MG available from leading China suppliers. Our factory provides high-purity GLP-1 and Glucagon dual agonists for effective weight management.

SupplierFuBai Peptidewww.glpfactory.com
Source categories

About this product

Product information from the supplier.

Mazdutide (also identified as IBI362) represents a breakthrough in metabolic pharmacology, engineered as a high-potency dual agonist targeting both the Glucagon-Like Peptide-1 (GLP-1) and Glucagon (GCG) receptors. As a sophisticated analog of the endogenous hormone oxyntomodulin, Mazdutide is designed for once-weekly subcutaneous administration, offering a streamlined therapeutic approach to complex metabolic disorders.

Developed through a strategic collaboration between Eli Lilly and Innovent Biologics, this innovative peptide leverages a synergistic mechanism of action. By simultaneously activating GLP-1 and GCG pathways, Mazdutide effectively reduces appetite while potentially enhancing energy expenditure, providing a comprehensive pharmacological strategy for significant weight management and glycemic control.

Detailed Parameters

Product NameMazdutide (IBI362) MechanismGLP-1 / Glucagon Dual Agonist
Hormone AnalogOxyntomodulin Analog AdministrationInjectable (Subcutaneous)
FrequencyOnce-weekly Primary TargetWeight Loss & Metabolism
DevelopersEli Lilly & Innovent Biologics CategoryGenetic Engineering Peptide
Main EffectsAppetite Reduction & Energy Increase Pharmaceutical GradeHigh Purity Bio-pharmaceutical

Key Advantages

Dual Receptor Action

Combines GLP-1 and GCG agonism to target weight loss from two distinct biological pathways for superior results.

Weekly Administration

Engineered for once-weekly dosing, significantly improving patient compliance compared to daily treatments.

Metabolic Synergy

Promotes weight reduction not only by suppressing hunger but by potentially increasing the body's energy expenditure.

Advanced Bio-Engineering

Utilizes cutting-edge genetic engineering techniques to ensure high stability and precise receptor binding.

Precision Design

An optimized analog of oxyntomodulin tailored for maximum pharmacological efficacy in human subjects.

Global R&D Standard

Developed by industry leaders in biologics, ensuring rigorous quality control and clinical validation.

Product Gallery

Management Platforms

Cold Chain Logistics

Strict temperature-controlled storage to maintain peptide stability and biological activity.

Purity Analysis

Advanced HPLC and Mass Spectrometry testing for every batch to ensure pharmaceutical grade purity.

Stability Monitoring

Real-time tracking of peptide degradation rates under various environmental conditions.

Regulatory Compliance

Full adherence to international bio-manufacturing standards and genetic engineering guidelines.

Inventory Precision

Smart warehouse management ensuring FIFO protocols for biological product freshness.

Batch Traceability

Complete digital audit trails from raw amino acid synthesis to final injectable formulation.

Investment Return Comparison

Feature MetricStandard PeptidesMazdutide (Dual Agonist)
Mechanism RangeSingle ReceptorDual Receptor (GLP-1/GCG)
Patient ComplianceDaily/FrequentOnce-Weekly
Metabolic ImpactAppetite SuppressionAppetite + Energy Expenditure
Weight Loss PotentialModerate to HighEnhanced Synergy
R&D ComplexityConventionalAdvanced Genetic Engineering

Frequently Asked Questions

Q: What makes Mazdutide different from traditional GLP-1 agonists?

Unlike traditional agonists that only target the GLP-1 receptor, Mazdutide is a dual agonist that targets both GLP-1 and Glucagon (GCG) receptors, potentially increasing energy expenditure alongside appetite reduction.

Q: How is Mazdutide administered in a clinical setting?

Mazdutide is designed as an injectable medication, typically administered via a subcutaneous injection once per week.

Q: What is the role of genetic engineering in the production of Mazdutide?

Genetic engineering allows for the precise synthesis of the peptide sequence, ensuring it functions as a stable analog of oxyntomodulin with optimized binding affinity for target receptors.

Q: Which companies were involved in the development of Mazdutide?

Mazdutide was developed through a collaborative effort between the global pharmaceutical giant Eli Lilly and Innovent Biologics.

Q: How does the dual agonism affect energy expenditure?

The glucagon (GCG) receptor component of the dual agonist is believed to stimulate thermogenesis and increase the rate at which the body burns calories, complementing the weight loss induced by GLP-1.

Q: Is Mazdutide considered a peptide drug?

Yes, Mazdutide is a peptide-based medication, specifically a modified amino acid chain designed to mimic natural hormones for therapeutic effects.

Ready to Access Premium Genetic Engineering Peptides?

Contact Us